Evidence map›Paper›PMID 31326980›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Effectiveness of Monovalent Rotavirus Vaccine Against Hospitalization With Acute Rotavirus Gastroenteritis in Kenyan Children.

Sammy Khagayi, Richard Omore, Grieven P Otieno, Billy Ogwel, John B Ochieng, Jane Juma, Evans Apondi, Godfrey Bigogo, Clayton Onyango, Mwanajuma Ngama and 12 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Effectiveness of RotarixWellcome open research · 2020
    Pooled it
  4. Trial
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. The Enterics for Global Health (EFGH)Open forum infectious diseases · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Sammy KhagayiCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu.
Richard OmoreCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu.
Grieven P OtienoCentre for Geographic Medicine Research-Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, and.
Billy OgwelCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu.
John B OchiengCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu.
Jane JumaCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu.
Evans ApondiCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu.
Godfrey BigogoCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu.
Clayton OnyangoDivision of Global Health Protection, Centers for Disease Control and Prevention (CDC)-Kenya, Kisumu, Kenya.
Mwanajuma NgamaCentre for Geographic Medicine Research-Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, and.
Regina NjeruCentre for Geographic Medicine Research-Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, and.
Betty E OworCentre for Geographic Medicine Research-Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, and.
Mike J MwangaCentre for Geographic Medicine Research-Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, and.
Yaw AddoEmory Global Health Institute, Emory University, Atlanta, Georgia.
Collins TabuNational Vaccines and Immunisations Programme, and.
Anyangu AmwayiDisease Surveillance and Response Unit, Ministry of Health, Nairobi, Kenya.
Jason M MwendaWorld Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.
Jacqueline E TateViral Gastroenteritis Branch, Division of Viral Diseases, CDC, Atlanta, Georgia.
Umesh D ParasharViral Gastroenteritis Branch, Division of Viral Diseases, CDC, Atlanta, Georgia.
Robert F BreimanEmory Global Health Institute, Emory University, Atlanta, Georgia.
D James NokesCentre for Geographic Medicine Research-Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, and.
Jennifer R VeraniDivision of Global Health Protection, CDC-Kenya, Nairobi, Kenya; and.

Funding

Wellcome Trust 102975Wellcome Trust 203077World Health Organization 001
6 · The paper itself

Abstract

backgroundRotavirus remains a leading cause of pediatric diarrheal illness and death worldwide. Data on rotavirus vaccine effectiveness in sub-Saharan Africa are limited. Kenya introduced monovalent rotavirus vaccine (RV1) in July 2014. We assessed RV1 effectiveness against rotavirus-associated hospitalization in Kenyan children.

methodsBetween July 2014 and December 2017, we conducted surveillance for acute gastroenteritis (AGE) in 3 Kenyan hospitals. From children age-eligible for ≥1 RV1 dose, with stool tested for rotavirus and confirmed vaccination history we compared RV1 coverage among rotavirus positive (cases) vs rotavirus negative (controls) using multivariable logistic regression and calculated effectiveness based on adjusted odds ratio.

resultsAmong 677 eligible children, 110 (16%) were rotavirus positive. Vaccination data were available for 91 (83%) cases; 51 (56%) had 2 RV1 doses and 33 (36%) 0 doses. Among 567 controls, 418 (74%) had vaccination data; 308 (74%) had 2 doses and 69 (16%) 0 doses. Overall 2-dose effectiveness was 64% (95% confidence interval [CI], 35%-80%); effectiveness was 67% (95% CI, 30%-84%) for children aged <12 months and 72% (95% CI, 10%-91%) for children aged ≥12 months. Significant effectiveness was seen in children with normal weight for age, length/height for age and weight for length/height; however, no protection was found among underweight, stunted, or wasted children.

conclusionsRV1 in the Kenyan immunization program provides significant protection against rotavirus-associated hospitalization which persisted beyond infancy. Malnutrition appears to diminish vaccine effectiveness. Efforts to improve rotavirus uptake and nutritional status are important to maximize vaccine benefit.

Indexed as

GastroenteritisRotavirusRotavirus InfectionsRotavirus VaccinesChildHospitalizationHumansInfantKenyaVaccinationVaccines, AttenuatedRotavirus VaccinesVaccines, Attenuatedacute gastroenteritisKenyarotavirusvaccine effectiveness

Identifiers

PMID31326980
PMCPMC7245145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.